Stock ENTA ENANTA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Enanta Pharmaceuticals, Inc.

Equities

ENTA

US29251M1062

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
16.15 USD -1.82% Intraday chart for Enanta Pharmaceuticals, Inc. -1.28% +71.63%
Feb. 09 Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating MT
Feb. 07 Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024

Business Summary

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).

Number of employees: 145

Sales per Business

USD in Million2022Weight2023Weight Delta
Small Molecule Drugs
100.0 %
86 100.0 % 79 100.0 % -8.07%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
86 100.0 % 79 100.0 % -8.07%

Managers

Managers TitleAgeSince
Jay Luly CEO
 Chief Executive Officer 67 03-06-30
Paul Mellett DFI
 Director of Finance/CFO 68 03-08-31
Scott Rottinghaus CTO
 Chief Tech/Sci/R&D Officer 50 22-08-07
Yat Sun Or CTO
 Chief Tech/Sci/R&D Officer 72 99-10-31
Jennifer Viera IRC
 Investor Relations Contact - 22-12-31
Brendan Luu PRN
 Corporate Officer/Principal 49 21-01-25
Tara Kieffer PRN
 Corporate Officer/Principal 46 20-12-07

Members of the board

Members of the board TitleAgeSince
Mark Foletta BRD
 Director/Board Member 63 20-06-28
Lesley Russell BRD
 Director/Board Member 63 16-11-17
Bruce Carter CHM
 Chairman 80 13-11-24
Jay Luly CEO
 Chief Executive Officer 67 03-06-30
Terry Vance BRD
 Director/Board Member 67 11-05-31
Yujiro Hata BRD
 Director/Board Member 49 21-08-18
Kristine Peterson BRD
 Director/Board Member 64 17-09-12

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 21,155,983 19,865,549 ( 93.90 %) 0 93.90 %

Shareholders

NameEquities%Valuation
Armistice Capital LLC
9.756 %
2,064,000 9.756 % 36 M $
Farallon Capital Management LLC
9.572 %
2,025,000 9.572 % 35 M $
BlackRock Advisors LLC
8.797 %
1,861,120 8.797 % 32 M $
Vanguard Fiduciary Trust Co.
8.479 %
1,793,786 8.479 % 31 M $
Millennium Management LLC
6.215 %
1,314,949 6.215 % 23 M $
Morgan Stanley Investment Management, Inc.
5.545 %
1,173,058 5.545 % 20 M $
Acadian Asset Management LLC
3.984 %
842,944 3.984 % 15 M $
Jay Luly
3.832 %
810,609 3.832 % 14 M $
Wells Fargo Bank NA
3.666 %
775,591 3.666 % 14 M $
Millennium Management LLC
3.617 %
765,141 3.617 % 13 M $

Company contact information

Enanta Pharmaceuticals, Inc.

500 Arsenal Street

02472, Watertown

+617 607 0800

http://www.enanta.com
address Enanta Pharmaceuticals, Inc.(ENTA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Enanta Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
16.45 USD
Average target price
20.88 USD
Spread / Average Target
+26.90%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ENANTA PHARMACEUTICALS, INC. Stock Enanta Pharmaceuticals, Inc.
+72.21% 348M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.10% 42.63B
LONZA GROUP AG Stock Lonza Group AG
+50.98% 42.32B
MODERNA, INC. Stock Moderna, Inc.
+4.50% 40.26B
CELLTRION, INC. Stock Celltrion, Inc.
-11.36% 27.27B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.56% 25.24B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.76% 18.78B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.58% 12.39B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.80% 12.24B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.96% 10.95B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ENTA Stock
  4. Company Enanta Pharmaceuticals, Inc.